SCYNEXIS, Inc. (SCYX), a biotechnology company, has revealed its financial results for the first quarter of 2025 with a net loss of $5.4 million or $0.11 per share. The company's revenue significantly decreased from $1.4 million in Q1 2024 to $0.3 million in Q1 2025, marking a challenging financial period.\n\nIn a positive regulatory development, the FDA has lifted the clinical hold on SCYNEXIS's antifungal drug, ibrexafungerp, which allows the Phase 3 MARIO study for treating invasive candidiasis to resume. However, SCYNEXIS is currently in disagreement with GSK over the continuation of this study, as GSK has stated their intention to terminate it. Despite this, GSK remains committed to the commercialization of Brexafemme.\n\nMeanwhile, SCYNEXIS announced a strategic milestone with Hansoh Pharmaceutical Group, which received Chinese NMPA approval for ibrexafungerp in the treatment of acute vulvovaginal candidiasis (VVC). This approval paves the way for SCYNEXIS to receive future milestone payments and approximately 10% in royalties on sales in China.\n\nOn the development front, SCYNEXIS presented positive preclinical data for its second-generation fungerp candidate, SCY-247, which demonstrates potent antifungal activity against multi-drug-resistant fungi. The company anticipates reporting Phase 1 study results in Q3 2025, aligning with its strategy to expand its antifungal portfolio.\n\nFinancially, SCYNEXIS ended Q1 2025 with a strong cash position of $53.8 million, providing operational runway into Q3 2026. This follows a decrease in R&D expenses from $7.2 million to $5.1 million year-over-year, reflecting tighter cost management policies.

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News

SCYNEXIS, a biotechnology company, reported a net loss of $5.4 million in Q1 2025, with revenue declining to $0.3 million from $1.4 million in Q1 2024. The FDA lifted a clinical hold on its antifungal drug ibrexafungerp, allowing the Phase 3 MARIO study to resume, though disagreements with GSK over the study's continuation persist. SCYNEXIS secured Chinese NMPA approval for ibrexafungerp in VVC treatment, enabling future milestone payments and royalties. Preclinical data for its second-generation fungerp candidate SCY-247 was presented, with Phase 1 results expected in Q3 2025. The company ended Q1 2025 with $53.8 million in cash.